The TCR Therapy Market is poised for Transformation by Rising Prevalence of Cancer
Author : kajal patil | Published On : 22 Jan 2025
The TCR therapy market involves the engineering of T-cell receptors for developing engineered T-cell therapies targeting various cancers. TCR therapy utilizes a patient's own T cells, which are collected and genetically engineered to express a new TCR directed against cancer cells. Once reinfused into patients, these engineered T cells can eliminate cancerous cells. The engineered T cell receptors recognize cancer cell surface antigens like MAGE-A3 to direct the immune cells to tumors.
The TCR Therapy Market is estimated to be valued at USD 0.04 Bn in 2024 and is expected to reach USD 7.20 Bn by 2031, growing at a compound annual growth rate (CAGR) of 51.1% from 2024 to 2031.
Key Takeaways
Key players operating in the TCR therapy market are Gilead Sciences, TC Biopharm, Anthropic, Fate Therapeutics, Adicet Bio and Nkarta Therapeutics. These leading players are engaged in various clinical trials and collaborations to strengthen their product pipelines.
Growing prevalence of various cancers like lymphoma, lung cancer and melanoma globally is fueling the demand for novel targeted immunotherapy approaches like TCR therapy. According to Globocan 2020, there were an estimated 19.3 million new cancer cases and 10.0 million cancer deaths worldwide in 2020.
Leading pharmaceutical companies are expanding their TCR Therapy production facilities globally to cater to the growing demand. For instance, in 2022 Fate Therapeutics announced plans to develop a commercial-scale GMP facilities in San Diego for manufacturing engineered T cells including TCR therapies.
Market Key Trends
One of the key trends anticipated to shape the TCR therapy market is increasing focus on developing allogeneic “off-the-shelf” therapies. Allogeneic therapies utilize T cells derived from healthy donors instead of individual patients. This helps overcome limitations of autologous TCR therapies like lengthy manufacturing timelines and high costs. Companies are conducting clinical trials of allogeneic TCR-T therapies for conditions like HR+/HER2- breast cancer and acute myeloid leukemia.
Porter's Analysis
Threat of new entrants: High capital requirements and government approvals make entry difficult.
Bargaining power of buyers: Large pharmaceutical companies have strong negotiating power over small TCR therapy suppliers.
Bargaining power of suppliers: Suppliers of TCR therapy raw materials and equipment have some bargaining power as demand is growing rapidly.
Threat of new substitutes: TCR therapy faces a substitute threat from CAR-T therapy and other new immunotherapies under development.
Competitive rivalry: Intense competition exists between large pharmaceutical firms to gain market share through innovative R&D in TCR therapy.
North America currently dominates the TCR therapy market as of 2022, accounting for approximately 35% of the global market share. This is attributed to factors such as presence of key market players, established biopharmaceutical industry, rising cancer incidences, and growing adoptation of immunotherapy in the region.
The Asia Pacific region is poised to witness the fastest growth over the forecast period from 2024 to 2031. This is due to large patient pools, growing healthcare spending, increasing focus of international players on establishing manufacturing & research facilities, and rising awareness about advanced cancer treatment options in countries such as China and India.
Author Bio:
Vaagisha brings over three years of expertise as a content editor in the market research domain. Originally a creative writer, she discovered her passion for editing, combining her flair for writing with a meticulous eye for detail. Her ability to craft and refine compelling content makes her an invaluable asset in delivering polished and engaging write-ups.
(LinkedIn: https://www.linkedin.com/in/vaagisha-singh-8080b91)